Additive therapeutic effects of the liver extract preparation mixture adelavin-9 on interferon-β treatment for chronic hepatitis C

Hirotoshi Ebinuma, Hidetsugu Saito, Shinichirou Tada, Tetsuya Masuda, Tomoyoshi Kamiya, Jiro Nishida, Masahiro Yoshioka, Hiromasa Ishii

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background/Aims: We previously reported that intravenous interferon-β administration was effective in treating patients with chronic hepatitis C and that there was no significant correlation between the response to therapy and host in vitro immunoglobulin production. The aims of this study were to evaluate the additive effect of a liver extract preparation and flavin adenine dinucleotide mixture and to reevaluate the correlation. Methodology: 65 patients with chronic hepatitis C received intravenously 6 million units of interferon-β and 2mL of a liver extract preparation and flavin adenine dinucleotide mixture. The results of this study were compared with those of our previous study, on interferon-β monotherapy in 91 patients with chronic hepatitis C. In addition, peripheral blood mononuclear cells were obtained before interferon-β administration and cultured. Immunoglobulin concentrations in their supernatants were measured and the correlation with the interferon response was evaluated. Results: The virological end-of-treatment or sustained response occurred in 49 of 58 cases (84.5%), and 16 of 58 cases (27.6%), respectively. Biochemical end-of-treatment or sustained responses occurred in 22 of 58 cases (37.9%), and 30 of 58 cases (51.7%), respectively. These response rates were higher than those reported in our previous study of interferon monotherapy. Monovariate analysis indicated that the use of the liver extract preparation and flavin adenine dinucleotide mixture was a significant predictor of the virological end-of-treatment response and the sustained biochemical response, but by multivariate analysis these relationships were not significant. Immunoglobulin production was not correlated with the virological and biochemical responses. Conclusions: This study indicated that combination therapy with intravenous interferon-β and the liver extract preparation and flavin adenine dinucleotide mixture was more effective than intravenous interferon-β monotherapy. However, no correlation between the interferon response and in vitro immunoglobulin production was observed.

Original languageEnglish
Pages (from-to)1109-1114
Number of pages6
JournalHepato-Gastroenterology
Volume51
Issue number58
Publication statusPublished - 2004 Jul

Fingerprint

Liver Extracts
Therapeutic Uses
Chronic Hepatitis C
Interferons
Flavin-Adenine Dinucleotide
Immunoglobulins
Therapeutics
Adelavin 9
Intravenous Administration
Blood Cells
Multivariate Analysis

Keywords

  • Chronic hepatitis C
  • In vitro immunoglobulin production
  • Interferon-β
  • Liver extract preparation and flavin adenine dinucleotide mixture

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Additive therapeutic effects of the liver extract preparation mixture adelavin-9 on interferon-β treatment for chronic hepatitis C. / Ebinuma, Hirotoshi; Saito, Hidetsugu; Tada, Shinichirou; Masuda, Tetsuya; Kamiya, Tomoyoshi; Nishida, Jiro; Yoshioka, Masahiro; Ishii, Hiromasa.

In: Hepato-Gastroenterology, Vol. 51, No. 58, 07.2004, p. 1109-1114.

Research output: Contribution to journalArticle

Ebinuma, H, Saito, H, Tada, S, Masuda, T, Kamiya, T, Nishida, J, Yoshioka, M & Ishii, H 2004, 'Additive therapeutic effects of the liver extract preparation mixture adelavin-9 on interferon-β treatment for chronic hepatitis C', Hepato-Gastroenterology, vol. 51, no. 58, pp. 1109-1114.
Ebinuma, Hirotoshi ; Saito, Hidetsugu ; Tada, Shinichirou ; Masuda, Tetsuya ; Kamiya, Tomoyoshi ; Nishida, Jiro ; Yoshioka, Masahiro ; Ishii, Hiromasa. / Additive therapeutic effects of the liver extract preparation mixture adelavin-9 on interferon-β treatment for chronic hepatitis C. In: Hepato-Gastroenterology. 2004 ; Vol. 51, No. 58. pp. 1109-1114.
@article{5cea3f5945fd4f88aa551be2ea4308ee,
title = "Additive therapeutic effects of the liver extract preparation mixture adelavin-9 on interferon-β treatment for chronic hepatitis C",
abstract = "Background/Aims: We previously reported that intravenous interferon-β administration was effective in treating patients with chronic hepatitis C and that there was no significant correlation between the response to therapy and host in vitro immunoglobulin production. The aims of this study were to evaluate the additive effect of a liver extract preparation and flavin adenine dinucleotide mixture and to reevaluate the correlation. Methodology: 65 patients with chronic hepatitis C received intravenously 6 million units of interferon-β and 2mL of a liver extract preparation and flavin adenine dinucleotide mixture. The results of this study were compared with those of our previous study, on interferon-β monotherapy in 91 patients with chronic hepatitis C. In addition, peripheral blood mononuclear cells were obtained before interferon-β administration and cultured. Immunoglobulin concentrations in their supernatants were measured and the correlation with the interferon response was evaluated. Results: The virological end-of-treatment or sustained response occurred in 49 of 58 cases (84.5{\%}), and 16 of 58 cases (27.6{\%}), respectively. Biochemical end-of-treatment or sustained responses occurred in 22 of 58 cases (37.9{\%}), and 30 of 58 cases (51.7{\%}), respectively. These response rates were higher than those reported in our previous study of interferon monotherapy. Monovariate analysis indicated that the use of the liver extract preparation and flavin adenine dinucleotide mixture was a significant predictor of the virological end-of-treatment response and the sustained biochemical response, but by multivariate analysis these relationships were not significant. Immunoglobulin production was not correlated with the virological and biochemical responses. Conclusions: This study indicated that combination therapy with intravenous interferon-β and the liver extract preparation and flavin adenine dinucleotide mixture was more effective than intravenous interferon-β monotherapy. However, no correlation between the interferon response and in vitro immunoglobulin production was observed.",
keywords = "Chronic hepatitis C, In vitro immunoglobulin production, Interferon-β, Liver extract preparation and flavin adenine dinucleotide mixture",
author = "Hirotoshi Ebinuma and Hidetsugu Saito and Shinichirou Tada and Tetsuya Masuda and Tomoyoshi Kamiya and Jiro Nishida and Masahiro Yoshioka and Hiromasa Ishii",
year = "2004",
month = "7",
language = "English",
volume = "51",
pages = "1109--1114",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "58",

}

TY - JOUR

T1 - Additive therapeutic effects of the liver extract preparation mixture adelavin-9 on interferon-β treatment for chronic hepatitis C

AU - Ebinuma, Hirotoshi

AU - Saito, Hidetsugu

AU - Tada, Shinichirou

AU - Masuda, Tetsuya

AU - Kamiya, Tomoyoshi

AU - Nishida, Jiro

AU - Yoshioka, Masahiro

AU - Ishii, Hiromasa

PY - 2004/7

Y1 - 2004/7

N2 - Background/Aims: We previously reported that intravenous interferon-β administration was effective in treating patients with chronic hepatitis C and that there was no significant correlation between the response to therapy and host in vitro immunoglobulin production. The aims of this study were to evaluate the additive effect of a liver extract preparation and flavin adenine dinucleotide mixture and to reevaluate the correlation. Methodology: 65 patients with chronic hepatitis C received intravenously 6 million units of interferon-β and 2mL of a liver extract preparation and flavin adenine dinucleotide mixture. The results of this study were compared with those of our previous study, on interferon-β monotherapy in 91 patients with chronic hepatitis C. In addition, peripheral blood mononuclear cells were obtained before interferon-β administration and cultured. Immunoglobulin concentrations in their supernatants were measured and the correlation with the interferon response was evaluated. Results: The virological end-of-treatment or sustained response occurred in 49 of 58 cases (84.5%), and 16 of 58 cases (27.6%), respectively. Biochemical end-of-treatment or sustained responses occurred in 22 of 58 cases (37.9%), and 30 of 58 cases (51.7%), respectively. These response rates were higher than those reported in our previous study of interferon monotherapy. Monovariate analysis indicated that the use of the liver extract preparation and flavin adenine dinucleotide mixture was a significant predictor of the virological end-of-treatment response and the sustained biochemical response, but by multivariate analysis these relationships were not significant. Immunoglobulin production was not correlated with the virological and biochemical responses. Conclusions: This study indicated that combination therapy with intravenous interferon-β and the liver extract preparation and flavin adenine dinucleotide mixture was more effective than intravenous interferon-β monotherapy. However, no correlation between the interferon response and in vitro immunoglobulin production was observed.

AB - Background/Aims: We previously reported that intravenous interferon-β administration was effective in treating patients with chronic hepatitis C and that there was no significant correlation between the response to therapy and host in vitro immunoglobulin production. The aims of this study were to evaluate the additive effect of a liver extract preparation and flavin adenine dinucleotide mixture and to reevaluate the correlation. Methodology: 65 patients with chronic hepatitis C received intravenously 6 million units of interferon-β and 2mL of a liver extract preparation and flavin adenine dinucleotide mixture. The results of this study were compared with those of our previous study, on interferon-β monotherapy in 91 patients with chronic hepatitis C. In addition, peripheral blood mononuclear cells were obtained before interferon-β administration and cultured. Immunoglobulin concentrations in their supernatants were measured and the correlation with the interferon response was evaluated. Results: The virological end-of-treatment or sustained response occurred in 49 of 58 cases (84.5%), and 16 of 58 cases (27.6%), respectively. Biochemical end-of-treatment or sustained responses occurred in 22 of 58 cases (37.9%), and 30 of 58 cases (51.7%), respectively. These response rates were higher than those reported in our previous study of interferon monotherapy. Monovariate analysis indicated that the use of the liver extract preparation and flavin adenine dinucleotide mixture was a significant predictor of the virological end-of-treatment response and the sustained biochemical response, but by multivariate analysis these relationships were not significant. Immunoglobulin production was not correlated with the virological and biochemical responses. Conclusions: This study indicated that combination therapy with intravenous interferon-β and the liver extract preparation and flavin adenine dinucleotide mixture was more effective than intravenous interferon-β monotherapy. However, no correlation between the interferon response and in vitro immunoglobulin production was observed.

KW - Chronic hepatitis C

KW - In vitro immunoglobulin production

KW - Interferon-β

KW - Liver extract preparation and flavin adenine dinucleotide mixture

UR - http://www.scopus.com/inward/record.url?scp=3042660487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042660487&partnerID=8YFLogxK

M3 - Article

C2 - 15239256

AN - SCOPUS:3042660487

VL - 51

SP - 1109

EP - 1114

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 58

ER -